DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,500 | -5.0% | 275,107 | +3.7% | 0.40% | -5.0% |
| Q2 2023 | $63,699 | +12.8% | 265,412 | +18.4% | 0.42% | +5.8% |
| Q1 2023 | $56,486 | -6.6% | 224,116 | -1.7% | 0.40% | -13.2% |
| Q4 2022 | $60,485 | -99.9% | 227,882 | -34.7% | 0.46% | -34.5% |
| Q3 2022 | $90,081,000 | +2.2% | 348,758 | +0.4% | 0.70% | +7.3% |
| Q2 2022 | $88,099,000 | -9.5% | 347,505 | +4.7% | 0.65% | +13.5% |
| Q1 2022 | $97,360,000 | +19.3% | 331,914 | +33.6% | 0.57% | +36.0% |
| Q4 2021 | $81,598,000 | +0.3% | 248,418 | -7.0% | 0.42% | -5.8% |
| Q3 2021 | $81,324,000 | +14.9% | 267,126 | +1.2% | 0.45% | +2.5% |
| Q2 2021 | $70,808,000 | +4.8% | 263,853 | -12.1% | 0.44% | -2.2% |
| Q1 2021 | $67,568,000 | +57.8% | 300,195 | +55.7% | 0.44% | +51.4% |
| Q4 2020 | $42,816,000 | +15.4% | 192,742 | +11.8% | 0.29% | +8.5% |
| Q3 2020 | $37,115,000 | +68.1% | 172,363 | +38.0% | 0.27% | +52.2% |
| Q2 2020 | $22,081,000 | -37.1% | 124,874 | -50.7% | 0.18% | -2.2% |
| Q1 2020 | $35,092,000 | +74.1% | 253,534 | +93.1% | 0.18% | +15.2% |
| Q4 2019 | $20,152,000 | +1.8% | 131,303 | -4.2% | 0.16% | -5.4% |
| Q3 2019 | $19,788,000 | +17.4% | 137,006 | +16.2% | 0.17% | +15.2% |
| Q2 2019 | $16,853,000 | +14.9% | 117,919 | +6.2% | 0.14% | +8.2% |
| Q1 2019 | $14,663,000 | +31.0% | 111,069 | +2.3% | 0.13% | +34.0% |
| Q4 2018 | $11,196,000 | -2.7% | 108,571 | +2.6% | 0.10% | +14.9% |
| Q3 2018 | $11,502,000 | +5.9% | 105,856 | -3.8% | 0.09% | -6.5% |
| Q2 2018 | $10,860,000 | +53.7% | 110,056 | +52.5% | 0.09% | +36.8% |
| Q1 2018 | $7,065,000 | -31.2% | 72,154 | -34.8% | 0.07% | -22.7% |
| Q4 2017 | $10,276,000 | +8.1% | 110,710 | -0.1% | 0.09% | +2.3% |
| Q3 2017 | $9,508,000 | +6.0% | 110,837 | +4.2% | 0.09% | 0.0% |
| Q2 2017 | $8,974,000 | -65.2% | 106,337 | -65.4% | 0.09% | -28.9% |
| Q1 2017 | $25,752,000 | +231.6% | 307,497 | +208.3% | 0.12% | +30.1% |
| Q4 2016 | $7,765,000 | -0.9% | 99,750 | -0.2% | 0.09% | +9.4% |
| Q3 2016 | $7,832,000 | +5.9% | 99,912 | +3.4% | 0.08% | +2.4% |
| Q2 2016 | $7,396,000 | -18.5% | 96,612 | +1.0% | 0.08% | -18.6% |
| Q1 2016 | $9,070,000 | +0.2% | 95,612 | -1.8% | 0.10% | -12.8% |
| Q4 2015 | $9,048,000 | – | 97,412 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |